Revolution Medicines Quarterly Cash Flow Statement
NASDAQ: RVMDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 189.49 -0.14%
Revolution Medicines free cash flow
In the quarter ended Jun 30, 2026, Revolution Medicines generated -$387.3 million of operating cash flow and spent $2.3 million on capital expenditures. That left free cash flow of -$389.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
Revolution Medicines cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -644.37M | -453.82M | -364.89M | -305.21M | -247.79M | -213.42M | -194.57M | -156.29M | -133.23M | -116.00M | -161.54M | -108.43M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 2.45M | 2.35M | 2.27M | 1.53M | 2.29M | 1.69M | 1.74M | 1.64M | 1.64M | 1.54M | 1.30M | 1.30M |
| Stock-Based Compensation | 67.00M | 87.30M | 33.70M | 30.78M | 28.83M | 25.08M | 22.44M | 20.77M | 19.77M | 16.21M | 25.43M | 13.67M |
| Change in Working Capital | -25.51M | 6.39M | -13.88M | 14.19M | 1.40M | -1.84M | 24.25M | 1.57M | -12.43M | -28.30M | 21.11M | 1.91M |
| Operating Cash Flow | -387.32M | -354.17M | -274.24M | -207.31M | -221.76M | -194.44M | -138.29M | -130.42M | -128.17M | -160.56M | -120.56M | -100.50M |
| Capital Expenditures | -2.29M | -1.54M | -1.93M | -3.35M | -7.45M | -3.27M | -1.22M | -3.52M | -2.40M | -3.17M | -2.32M | -2.54M |
| Investing Cash Flow | -1.66B | 172.62M | 74.88M | 24.85M | 34.28M | -15.95M | -392.90M | -21.47M | 107.94M | -247.97M | -380.40M | 77.35M |
| Financing Cash Flow | 2.42B | 238.74M | 365.66M | -1.59M | 256.58M | 874.00K | 873.80M | 77.29M | 7.50M | 810.00K | 839.35M | 1.01M |
| Net Change in Cash | 374.50M | 57.19M | 166.30M | -184.05M | 69.10M | -209.51M | 342.61M | -74.59M | -12.72M | -407.72M | 338.39M | -22.13M |
| Free Cash Flow | -389.61M | -355.70M | -276.16M | -210.66M | -229.21M | -197.70M | -139.51M | -133.94M | -130.57M | -163.73M | -122.88M | -103.03M |
This table shows 12 quarterly periods of Revolution Medicines's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RVMD's reporting calendar. What is a cash flow statement?